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Batna, AlgeriaAbstractThe objective of our study was to describe the molecular support of carbapenem resistance from randomly selected clinical isolates of
multidrug-resistant (MDR) Acinetobacter baumannii as a pilot study from the Hamad Medical Corporation (HMC), Qatar. Results of our
report will be used to study carbapenemases using molecular techniques in all isolated MDR A. baumannii. Forty-eight MDR A. baumannii
were randomly selected from isolates preserved at HMC. Identiﬁcation of all isolates was conﬁrmed by matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry. Antibiotic resistance was tested phenotypically by Phoenix and conﬁrmed by Etest. The
molecular support of carbapenemases (blaOXA-23, blaOXA-24, blaOXA-58, blaNDM) was investigated by real-time PCR. The epidemiologic
relatedness of the isolates was veriﬁed by phylogenetic analysis based on partial sequences of CsuE and blaOXA-51 genes. All 48 isolates
were identiﬁed as A. baumannii and were conﬁrmed to be resistant to most antibiotics, especially meropenem, imipenems, ciproﬂoxacin,
levoﬂoxacin, amikacin, gentamicin and most of the β-lactams; they were sensitive to colistin. All the isolates were positive for blaOXA-23
and negative for the other tested carbapenemase genes. Clonality analysis demonstrated that different lineages were actually circulating in
Qatar; and we suggest that an outbreak occurred in the medical intensive care unit of HMC between 2011 and 2012. Here we report
the emergence of MDR A. baumannii producing the carbapenemase OXA-23 in Qatar.
New Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: mhamed@hamad.qaIntroductionAcinetobacter species are strictly aerobic nonfermenting Gram-
negative coccobacilli if in the inactive phase or bacilli if in the
rapid-growth phase. The Acinetobacter calcoaceticus–Acinetobacter
baumannii complex comprises A. baumannii, A. pittii, A. nosocomialis,
A. lwofﬁi and the environmental species A. calcoaceticus. CommonNew Microbes and New Infections © 2016 The Authors. Published by El
This is an open access articommercial tests cannot differentiate among these species, as they
share the same phenotypic tests. For daily microbiology work,
speciation adds clinical value, as A. baumannii is the only species in
this genus that is clinically important [1,2].
For epidemiologic studies, it is important to know the
identity of the main strains or clones of the same species
causing infections, especially in outbreak investigations, by
determining virulence or resistance genes using genotypic
studies [3,4]. Different genotypic tests have been used to study
the relatedness of the Acinetobacter isolates to learn the sources
of outbreaks and epidemics and the modes of intrahospital or
regional transmission. These tests include PCR-based methods,
mainly pulsed-ﬁeld gel electrophoresis (PFGE), ampliﬁedNew Microbe and New Infect 2016; 11: 47–51
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TABLE 1. Demographic data of 48 patients
Characteristic n
Patient age
Adult 48
Child 1
Nationality
Qatari 14
Indian 6
Other 29
48 New Microbes and New Infections, Volume 11 Number C, May 2016 NMNIfragment-length polymorphism, PFGE followed by further
subtyping using variable number of tandem repeat loci and
ﬁnally multilocus sequence typing (clonality analysis), which is
considered a powerful and discriminatory tool [1,5,6].
Mechanisms of carbapenem resistance in A. baumannii are
mainly due to the production of carbapenemases, especiallyOXA-
type carbapenem-hydrolyzing (class D) β-lactamases, which are
either chromosomally located, like blaOXA-51, which become
expressed only when the insertion sequence ISAba1 element is
inserted upstream of the gene, or acquired, mostly blaOXA-23-like,
blaOXA-24-like and blaOXA-58-like subfamilies, and metallo-β-lacta-
mases (class B; blaIMP, blaVIM, blaNDM) [7]. Rapid diagnosis of
resistance helps clinicians adequatelymanage infection, contain the
spread of infection and decrease the toxic adverse effects of
antimicrobial drugs due to multiple trials of empirical treatment.
Qatar’s population structure is complex and unique:
approximately 93% of the population comprises expatriates
coming from different countries, mainly other Arab nations and
the Indian continent (http://www.gsdp.gov.qa/portal/page/
portal/ppc/PPC_home/ppc_news/ppc_ﬁles_upload/
populations_status_2012_en.pdf). The expatriate workforce is
kinetic; many people travel frequently—more than once a
year—to their home countries. This continuous travelling fa-
cilitates the transfer of many resistant bacteria. If one of these
multidrug-resistant (MDR) organisms such as A. baumannii
gained access to the hospital, it is not easy to eliminate it, as the
hospital environment favours its growth and transmission
either by colonizing or infecting healthcare workers or living
within bioﬁlms formed by the bacteria, thus protecting it from
the effects of common disinfectants.
A recent study in Qatar described the mechanisms of car-
bapenem resistance in eight A. baumannii isolates [8]. Ours is
the second study to describe the genetic causes of carbapenem
resistance among 48 MDR A. baumannii isolates. The objective
of our study was to determine carbapenem resistance genes in
a randomly selected number of MDR A. baumannii from isolates
stored at Hamad Medical Corporation (HMC), Qatar, and to
learn whether they were genetically related. The outcome of
our study will help inform a project studying the magnitude of
MDR A. baumannii in the last few years, the common resistance
genes and the dominant clones circulating in Qatar. HMC
(comprising tertiary, general and continuing care hospitals) is
the principal public healthcare provider for the state of Qatar.Death 15
Length of stay
>1 year 6
2–6 months 19
Treatment received
Materials and MethodsColistin 33
Tigecycline 5
Comorbidities 27
Diabetes mellitus 21
Polytrauma 6
Coinfection with Pseudomonas aeruginosa 17Bacterial strains
Forty-eight MDR A. baumannii samples of the period
2011–2012 were randomly chosen. Isolates were taken fromNew Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of
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department, which is Qatar’s premier not-for-proﬁt health-
care provider. Located in the state of Qatar, HMC manages
eight hospitals (approximately 2600-bed capacity). All isolates
were sent to Marseille in chocolate agar slants at room
temperature.
Identiﬁcation and antibacterial susceptibility testing
Forty-eight MDR A. baumannii were identiﬁed, and antibiotic
susceptibility testing was performed by the broth microdilution
method (BD Phoenix; Becton Dickinson, Franklin Lakes, NJ,
USA) and conﬁrmed for identiﬁcation at URMITE (Unité des
Maladies Infectieuses et Tropicales Emergentes), Marseille,
France, by matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-TOF) using a MS LT spec-
trometer (Bruker Daltonics, Bremen, Germany) as previously
described [9], with ﬂex control software (Bruker) and MALDI
Biotyper version 3.0. A score of 1.9 was considered positive
for identiﬁcation at the species level, as previously reported [9].
Conﬁrmation of resistance by Etest (bioMérieux, Marcy l’Etoile,
France) was performed. The susceptibility breakpoints used
were those recommended in 2013 by the Clinical and Labo-
ratory Standards Institute (M100-S23). Susceptibility testing by
Etest was additionally done in Marseille to the following anti-
biotics: colistin, imipenem and sulbactam (AB Biodisk, Solna,
Sweden).
The 48 isolates were collected mainly from respiratory
specimens (n = 10); 11 of the patients were from the intensive
care unit (ICU), two from the coronary care unit, 12 from the
medical intensive care unit (MICU), one from the paediatric
intensive care unit, ﬁve from the surgical intensive care unit and
eight from the trauma intensive care unit (TICU) (Table 1).
Twenty-seven patients had comorbidities, and 15 patients died,
ten of whom were ICU patients.European Society of Clinical Microbiology and Infectious Diseases, NMNI, 11, 47–51
nses/by-nc-nd/4.0/)
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oxacillinases
DNA was extracted using the EZ1 advanced XL extractor with
DNA bacteria card and the EZ1 DNA Tissue Kit (Qiagen,
Courtaboeuf, France) according to the manufacturer’s in-
structions. All 48 A. baumannii isolates were screened for the
presence of resistance genes blaOXA-23, blaOXA-24, blaOXA-58
and blaNDM by real-time PCR (C1000 Themal Cycler; Bio-Rad,
Hercules, CA, USA). Ampliﬁcation was performed using the
following thermocycler conditions: initial denaturation step at
95°C for 15 minutes, followed by 35 cycles of denaturation at
95°C for 30 seconds and extension at 60°C for 1 minute.
Negative and positive controls were included in each assay.
Clonality analysis
The 48 isolates were subjected to molecular typing by clonality
analysis. Genotyping was performed using the genes blaOXA51-
like and CsuE, as previously described [10]. PCR ampliﬁcation,
sequencing and correction of gene sequences were performed
as previously described [10]. For each of the two genes, the
DNA sequences obtained from our isolates were aligned with
those of the reference strains by Clustal W software. The
phylogenetic relationship of our strains together with the3, 5, 6, 7, 10, 11, 1
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FIG. 1. Phylogenetic tree of concatenated partial sequences of CsuE and bla
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with the Kimura two-parameter model and bootstrap analyses
based on 1000 replications [11].ResultsAll isolates were conﬁrmed as A. baumannii by MALDI-TOF
Microﬂex (Bruker).
All isolates were resistant to imipenem, meropenem, cip-
roﬂoxacin, levoﬂoxacin, amikacin, gentamicin, sulfamethoxa-
zole/trimethoprim, amoxicillin/clavulanic acid, piperacillin/
tazobactam, cefotaxime and ceftazidime; 39 isolates were
resistant to sulbactam.
The colistin resistance rate was 0 (0/48), so treatment of
these patients with colistin would be suitable unless otherwise
contraindicated. All 48 isolates were positive for blaOXA-23;
none was positive for blaOXA-24, blaOXA-58 or blaNDM.
Clonality analysis typing revealed the existence of two pre-
dominant genotypes (Fig. 1). The ﬁrst genotype was the most
frequent (20 isolates), six of which were isolated from the
MICU in 2011. The second most frequent genotype was iso-
lated from ten isolates (after excluding one wrongly included6, 17,18, 19, 22, 23, 24, 25, 29, 31, 41, 43, 46, 48 
 26, 30, 34, 36, 45 
 BJAB0868
BJAB07104
i BJAB0715
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AYE
No. Strain Unit Date of 
isolation
year
1 3 MICU November 2011
2 5 MICU June 2011
3 10 MICU August 2011
4 19 MICU April  2011
5 23 MICU May 2011
6 47 MICU February 2011
7 26 MICU April 2011
8 8 MICU October 2012
9 2 MICU December 2012
10 22 MICU july 2012
11 30 MICU August 2012
12 36 MICU August 2012
2011
2012
ylogenetic tree
OXA-51 genes.
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the existence of an outbreak in the MICU, but because the
isolates were chosen randomly, conﬁrmation of an outbreak
cannot be done except after a clonality study of all isolated
A. baumannii during the 2 years to determine the isolation of
certain genotypes from the MICU.DiscussionMDR A. baumannii has emerged globally in both community and
hospital settings, causing many outbreaks, especially in ICUs
[12]. In our study, 28 of 48 patients were from ICUs. Resistance
to carbapenems among these isolates left no options for
treatment except colistin, which has many adverse effects,
including nephrotoxicity and neurotoxicity which affect mainly
debilitated persons [13,14]. In HMC, approximately 60% of
A. baumannii isolated from clinically signiﬁcant samples are
MDR; in our study, we found 48 MDR A. baumannii clinical
isolates which were randomly selected during the period
2011–2012 from isolates stored in the cryobank of HMC as a
pilot study. In addition to describing the molecular character-
ization of carbapenems resistance in A. baumannii, we also
studied the genetic relatedness of these isolates. Results of our
report will be used to study all MDR A. baumannii isolated in the
previous years to describe the magnitude of resistance in this
organism and to learn which common genotypes are circulating
in Qatar.
All 48 isolates were positive for blaOXA-23. We detected no
New Delhi metallo-β-lactamase (NDM) in the studied isolates
even though Qatar’s population structure is composed of
different nationalities, including many expatriates coming from
the Indian subcontinent. Studying all A. baumannii stored in the
previous years is expected to reveal the presence of NDM. Our
results are comparable with a recent study of A. baumannii
which included seven hospitals in the Gulf Cooperation
Countries, including eight isolates from Qatar, all of which were
positive for blaOXA-23, as well as many other countries in the
region, including all isolates from Kuwait, Oman and United
Arab Emirates and 90% of isolates from Riyadh, Saudi Arabia;
38% from Bahrain were positive for blaOXA-23 [8].
NDM was detected in many countries in the Middle East in
Enterobacteriaceae and A. baumannii, including the United Arab
Emirates, Oman, Saudi Arabia and Kuwait [15–18].
By comparing different studies which were conducted in
the Middle East (Kuwait, Saudi Arabia, Egypt, Algeria, Yemen),
no speciﬁc carbapenemase was found to be conﬁned to the
region. In Egypt, three acquired class D carbapenemases
(blaOXA-23 in 72%, blaOXA-40 in 4%, blaOXA-58 in 20%) were
identiﬁed among studied carbapenem-resistant A. baumanniiNew Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of
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23, blaOXA-24 and blaOXA-58 were detected in 72.5, 45 and
37.5% respectively in isolated A. baumannii strains [20].
blaOXA-23 was detected in Riyadh and the Eastern Province,
with 53 and 79.5% respectively among nonsusceptible
A. baumannii (A. Ribeiro, paper presented at 22nd European
Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), 2012) [21].
In the United Arab Emirates, one study found blaOXA-23-like
and blaOXA-64-like genes in all three isolates under study [22]. In
Abu Dhabi, it was found that the blaOXA-23-like gene was
detected in 73.6% of all strains included in the study [23], while
the main oxacillinases in Bahrain were blaOXA-40-like, which is a
subgroup of the blaOXA-72-like gene (5/8). Found less frequently
were the blaOXA-58-like (1/8) and blaOXA-23-like (2/8) genes
[24]. A Yemeni study identiﬁed three MDR A. baumannii; the
blaOXA-51-like gene and the acquired carbapenemase blaOXA-23-
like gene were detected in all three strains [25].
Clonality analysis typing revealed high diversity within our
isolates, with predominance of two genotypes. The high di-
versity is explained by the diversity of the population of Qatar.
Clonal dissemination was observed in the MICU during
2011–2012; nonclonal spread occurred in whole hospital
wards and outpatient clinics.
In 1998, a Qatari study in an ICU in HMC revealed that all
A. baumannii were carbapenem susceptible, while another
study, performed between 2007 and 2008 on blood culture
isolates, found carbapenem resistance in more than one third of
the isolated A. baumannii (41.5%). In 2002, an outbreak in a
TICU in HMC occurred by carbapenem-resistant A. baumannii
which involved 20 patients admitted to the TICU during a 6-
month period. A typing study was not performed at that
time, but by comparing antibiograms of patient isolates to those
isolated from the environment, it was found that all isolates
shared the same antibiogram [26–28]. Given the occurrences
of MDR A. baumannii in HMC, especially in the MICU, it is clear
that stringent infection control measures need to be imple-
mented. Further, studying the occurrence of all A. baumannii in
previous years will provide insight into the presence of this
organism’s endemicity or epidemicity; there is also a need to
screen these wards to compare the environmental clones to
those isolated from patients.
In conclusion, studying molecular resistance genes and mo-
lecular the clonal relatedness provides insight into the trans-
mission of MDR A. baumannii within HMC. This study has
revealed the need to study all A. baumannii isolated in previous
years to conﬁrm the occurrence of the MICU outbreak of MDR
A. baumannii during the 2011–2012 period and to conﬁrm the
presence or absence of other resistance genes, such as NDM or
other metallo-β-lactamase resistance genes.European Society of Clinical Microbiology and Infectious Diseases, NMNI, 11, 47–51
nses/by-nc-nd/4.0/)
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